Generation Bio to Present at 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 4, 2019--Generation Bio, a company developing the first genetic medicines that can be re-dosed and titrated to effect for a lifetime of benefit, today announced the company will present at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2019.
President and Chief Executive Officer Geoff McDonough, M.D. will provide an overview of the company and anticipated milestones for 2019.
Date: Tuesday, January 8, 2019 Time: 8:30 a.m. PT Location: Westin St. Francis Hotel, Elizabethan C
About Generation Bio
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people to live unaffected by inherited disease. The company is using its proprietary ceDNA platform to create gene therapies with drug-like properties – delivering durable gene expression with the ability to re-dose for individual patient titration and for the potential to sustain effect over a lifetime. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.generationbio.com or follow @lifetimegenetx.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190104005042/en/
Stern Investor Relations
Marissa Picerno, Ten Bridge Communications
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL
SOURCE: Generation Bio
Copyright Business Wire 2019.
PUB: 01/04/2019 08:00 AM/DISC: 01/04/2019 08:01 AM